<html>
<head>PUBMED IDs for MOC31</head>
<body bgcolor='#C5F0F2'><h1>MOC31</h1><a href='https://pubmed.ncbi.nlm.nih.gov/10473805/'>An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy.</a> September 4  1999<br><a href='https://pubmed.ncbi.nlm.nih.gov/10725458/'>A rapid and versatile method for harnessing scFv antibody fragments with various biological effector functions.</a> March 22  2000<br><a href='https://pubmed.ncbi.nlm.nih.gov/11358833/'>The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy.</a> May 19  2001<br><a href='https://pubmed.ncbi.nlm.nih.gov/14695757/'>A nonviral carrier for targeted gene delivery to tumor cells.</a> December 27  2003<br><a href='https://pubmed.ncbi.nlm.nih.gov/24418860/'>Tufting enteropathy revisited: the utility of MOC31 (EpCAM) immunohistochemistry in diagnosis.</a> March 7  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/24528603/'>The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells.</a> February 18  2014<br></body></html>
